New Diagnostic Method for Prostate Cancer Identified

University College London (UCL) researchers have developed an AI-driven diagnostic tool to analyze prostate MRI scans, aiming to increase the accuracy of cancer detection and reduce unnecessary invasive biopsies. According to reporting by The Jerusalem Post on June 8, 2026, the system assists radiologists in identifying clinically significant prostate cancer more reliably than current manual methods.

Prostate cancer is the most common cancer found in men. Identifying it early is critical, but the current diagnostic process often involves a tension between missing aggressive tumors and over-diagnosing slow-growing ones.

How does AI improve prostate cancer detection?

The new tool developed by UCL operates as a second set of eyes for radiologists. It analyzes the imaging data from prostate MRIs to flag areas that are highly likely to contain clinically significant cancer, which are the tumors that require immediate medical intervention.

Standard diagnosis currently relies heavily on the Prostate Imaging-Reporting and Data System, or PI-RADS, which provides a score based on a radiologist’s visual assessment. According to The Jerusalem Post, the AI reduces the variability inherent in these manual scores by providing a standardized, data-driven analysis of the scan.

By distinguishing between aggressive malignancies and indolent, slow-growing tumors, the AI helps clinicians avoid treating patients who may never have developed symptoms from their cancer. This shift focuses treatment on those who need it most while sparing others from unnecessary procedures.

Why is reducing unnecessary biopsies important?

A biopsy is an invasive procedure where tissue samples are removed from the prostate. These procedures carry risks of infection, bleeding, and significant patient discomfort.

Many men currently undergo biopsies because their MRI shows a suspicious area that turns out to be benign or a non-threatening form of cancer. The UCL AI tool aims to lower this rate of false positives. If a radiologist and the AI both determine a lesion is low-risk, the patient may avoid an invasive biopsy entirely.

This approach addresses the long-standing medical challenge of over-diagnosis. When doctors find very slow-growing cancers that would not have caused harm during the patient’s lifetime, the subsequent treatments—such as surgery or radiation—can cause permanent side effects, including urinary and sexual dysfunction.

What are the next steps for this diagnostic method?

The AI tool is currently being tested in trials to verify its performance across diverse patient populations. Researchers at UCL are focusing on how the tool integrates into the existing clinical workflow without adding excessive time to the diagnostic process.

The goal is for the AI to provide a second opinion that radiologists can use to confirm their findings before recommending a biopsy. This collaborative model ensures that human expertise remains central to the diagnosis while leveraging the precision of machine learning.

Further validation is required to determine how much the tool reduces the overall number of biopsies performed in a standard hospital setting. Once these trials are complete, the method could be adopted more widely to standardize prostate cancer screening globally.